Literature DB >> 28406539

Mechanisms of drug-drug interaction between rifampicin and fusidic acid.

Florianne Bel1, Laurent Bourguignon1,2,3, Michel Tod1,2, Tristan Ferry4,5,6, Sylvain Goutelle1,2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28406539      PMCID： PMC5510078          DOI： 10.1111/bcp.13277

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  18 in total

1.  Mechanisms of drug-drug interaction between rifampicin and fusidic acid.

Authors:  Florianne Bel; Laurent Bourguignon; Michel Tod; Tristan Ferry; Sylvain Goutelle
Journal:  Br J Clin Pharmacol       Date:  2017-04-12       Impact factor: 4.335

2.  The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.

Authors:  Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2015-12       Impact factor: 8.739

3.  The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.

Authors:  Emmanuel Chigutsa; Marianne E Visser; Elizabeth C Swart; Paolo Denti; Sudeep Pushpakom; Deirdre Egan; Nicholas H G Holford; Peter J Smith; Gary Maartens; Andrew Owen; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

4.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration.

Authors:  U Loos; E Musch; J C Jensen; G Mikus; H K Schwabe; M Eichelbaum
Journal:  Klin Wochenschr       Date:  1985-12-02

5.  Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.

Authors:  Marc Weiner; Charles Peloquin; William Burman; Chi-Cheng Luo; Melissa Engle; Thomas J Prihoda; William R Mac Kenzie; Erin Bliven-Sizemore; John L Johnson; Andrew Vernon
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

6.  Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.

Authors:  Anshul Gupta; Jennifer J Harris; Jianrong Lin; James P Bulgarelli; Bruce K Birmingham; Scott W Grimm
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 7.  Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.

Authors:  R Elsby; C Hilgendorf; K Fenner
Journal:  Clin Pharmacol Ther       Date:  2012-10-10       Impact factor: 6.875

Review 8.  Impact of OATP transporters on pharmacokinetics.

Authors:  A Kalliokoski; M Niemi
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

9.  Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.

Authors:  Stephan R Vavricka; Jessica Van Montfoort; Huy Riem Ha; Peter J Meier; Karin Fattinger
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

Review 10.  Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.

Authors:  Yoshihisa Shitara; Kazuya Maeda; Kazuaki Ikejiri; Kenta Yoshida; Toshiharu Horie; Yuichi Sugiyama
Journal:  Biopharm Drug Dispos       Date:  2013-01       Impact factor: 1.627
View more
  4 in total

1.  Mechanisms of drug-drug interaction between rifampicin and fusidic acid.

Authors:  Florianne Bel; Laurent Bourguignon; Michel Tod; Tristan Ferry; Sylvain Goutelle
Journal:  Br J Clin Pharmacol       Date:  2017-04-12       Impact factor: 4.335

2.  Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections.

Authors:  Amélie Marsot; Amélie Ménard; Julien Dupouey; Laurent Allanioux; Olivier Blin; Romain Guilhaumou
Journal:  Br J Clin Pharmacol       Date:  2020-05-13       Impact factor: 4.335

3.  Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models.

Authors:  Wafi Siala; Hector Rodriguez-Villalobos; Prabhavathi Fernandes; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

4.  Dual-Drug Delivery via the Self-Assembled Conjugates of Choline-Functionalized Graft Copolymers.

Authors:  Katarzyna Niesyto; Aleksy Mazur; Dorota Neugebauer
Journal:  Materials (Basel)       Date:  2022-06-24       Impact factor: 3.748
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.